Despite a highly desirable rate of immuno-virological success, a decrease in eGFR (-14 ml/min) and a mild increase in lipids (+17 mg/dL total cholesterol) by 3 years from starting the combination elvitegravir/cobicistat/emtricitabine/tenofovir (E/C/FTC/TDF) was observed in persons living with HIV (PLWH) enrolled in clinical trials. Similar data from PLWH routinely seen for care are less frequently reported. Randomised studies have also shown an improvement of markers of kidney function in people switching from E/C/FTC/TDF to E/C/FTC/tenofovir alafenamide (TAF).
Two years of exposure to elvitegravir/cobicistat/emtricitabina/tenofovir (E/C/FTC/TDF): an overview of the trend in laboratory parameters in clinical practice.
G. Nunnari;G. F. Pellicanò.
2017-01-01
Abstract
Despite a highly desirable rate of immuno-virological success, a decrease in eGFR (-14 ml/min) and a mild increase in lipids (+17 mg/dL total cholesterol) by 3 years from starting the combination elvitegravir/cobicistat/emtricitabine/tenofovir (E/C/FTC/TDF) was observed in persons living with HIV (PLWH) enrolled in clinical trials. Similar data from PLWH routinely seen for care are less frequently reported. Randomised studies have also shown an improvement of markers of kidney function in people switching from E/C/FTC/TDF to E/C/FTC/tenofovir alafenamide (TAF).File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
